Stephens Investment Management Group LLC grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 15.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 139,420 shares of the company's stock after purchasing an additional 18,786 shares during the quarter. Stephens Investment Management Group LLC owned about 0.45% of Medpace worth $46,320,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of MEDP. Empowered Funds LLC raised its stake in Medpace by 32.5% in the fourth quarter. Empowered Funds LLC now owns 8,693 shares of the company's stock valued at $2,888,000 after purchasing an additional 2,130 shares in the last quarter. Wilmington Savings Fund Society FSB increased its position in Medpace by 46.1% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 767 shares of the company's stock valued at $255,000 after purchasing an additional 242 shares during the period. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in shares of Medpace during the 4th quarter valued at about $532,000. Financial Advocates Investment Management bought a new stake in shares of Medpace during the 4th quarter valued at about $423,000. Finally, Meritage Portfolio Management boosted its stake in shares of Medpace by 4.6% during the 4th quarter. Meritage Portfolio Management now owns 3,211 shares of the company's stock valued at $1,067,000 after purchasing an additional 142 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.
Medpace Stock Performance
Shares of MEDP traded up $8.61 during trading hours on Wednesday, hitting $336.47. 529,842 shares of the stock were exchanged, compared to its average volume of 264,594. The company has a market cap of $10.46 billion, a price-to-earnings ratio of 29.46, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The stock's 50-day moving average price is $343.90 and its two-hundred day moving average price is $348.96.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. On average, research analysts expect that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.
Analyst Upgrades and Downgrades
MEDP has been the topic of several analyst reports. Baird R W downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. TD Cowen dropped their price target on shares of Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Finally, William Blair restated an "outperform" rating on shares of Medpace in a research report on Tuesday, October 22nd. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $381.44.
Read Our Latest Analysis on MEDP
Medpace Profile
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
See Also
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
